Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry

Anthera's varespladib meets primary endpoint in phase 2 FRANCIS trial for the treatment of Acute Coronary Syndrome

 
- Favorable results for secondary endpoints support outcomes benefit

HAYWARD, CA – May 6, 2009 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C). All patients in the FRANCIS trial received once daily doses of 80mg of Lipitor® (atorvastatin calcium), plus 500mg of varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles.

Pappas Ventures closes on fourth fund

RESEARCH TRIANGLE PARK, N.C., March 10, 2009 — Pappas Ventures today announced the final closing of its fourth fund, a $102 million venture capital fund focused on the life sciences sector. Like its immediate predecessor funds, Pappas Ventures IV will invest in product-oriented biopharmaceutical companies, with a secondary focus on medical technologies.

Phase 2 Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

 
LONDON, SEPT. 6, 2008 - CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction. COL-144 is a highly potent and selective 5HT1F receptor agonist. The studies were presented in poster presentations at the European Headache and Migraine Trust International Congress 2008 in London, Sept. 4-7, 2008.

Plexxikon initiates Phase 1 Trial for PLX5568

 
BERKELEY, Calif., September 3, 2008--(Business Wire)--Plexxikon Inc. today announced that it has initiated a Phase 1 human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs: pain as well as polycystic kidney disease (PKD). PLX5568 has demonstrated robust preclinical efficacy in multiple pain models, including neuropathic pain as well as acute and inflammatory pain. In addition, PLX5568 has demonstrated compelling efficacy in multiple preclinical models of PKD.

MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers

 
MGCD265 Targets c-Met, VEGFs, Tie-2 and Ron Receptor Tyrosine Kinases

Initial Compound from Portfolio of Potent Multi-targeted Kinase Inhibitors

Montreal, Quebec. April 16, 2008 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data for MGCD265, an oral, multi-targeted (c-Met) kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.

TyRx Pharma raises $25 million

 
Proceeds Will Support Commercialization of the AIGISrx™ CRMD AntiBacterial Envelope and Development and Launch of Additional Drug-Eluting Devices in the TyRx Pipeline

Monmouth Junction, NJ, (February 27, 2008) -- TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. In connection with the financing, Jeffrey Leiden, M.D., Ph.D., Managing Director, and Scott Requadt, J.D., MBA, Principal, both of Clarus Ventures, and Arthur Pappas, Managing Partner, Pappas Ventures, will join TyRx's Board of Directors.

Athersys announces summary results for Phase 1 safety study of its novel obesity drug

 
CLEVELAND, Feb. 27, 2008 (PRIME NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced top-line results from its Phase 1 clinical trial of ATHX-105, its orally administered drug candidate for the treatment of obesity. ATHX-105 was well- absorbed, providing good drug exposures, well-tolerated up to high doses, and had no negative effect on cardiovascular, hematology or other clinical parameters.

MethylGene and Pharmion announce orphan drug designation for treatment of acute myelogenous leukemia

 
Montreal, Quebec and Boulder, Colorado. February 14, 2008 – MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States.